Author: Ravi Shankar

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
Rule 8.3 of the Takeover Code (the “Code”)

1. KEY INFORMATION

(a) Full name of discloser:	Man Group PLC
(b) Owner or controller of interests and short positions disclosed, if different from 1(a):  The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.
(c) Name of offeror/offeree in relation to whose relevant securities this form relates:  Use a separate form for each offeror/offeree	Gamma Communications plc
(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:
(e) Date position held/dealing undertaken:  For an opening position disclosure, state the latest practicable date prior to the disclosure	10/11/2026
(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?	NO

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:	0.25p ordinary
	Interests		Short positions
	Number	%	Number	%
(1) Relevant securities owned and/or controlled:	761,936	0.85
(2) Cash-settled derivatives:	343,103	0.38
(3) Stock-settled derivatives (including options) and agreements to purchase/sell:
TOTAL:	1,105,039	1.23

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b) Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:
Details, including nature of the rights concerned and relevant percentages:

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevant security

Purchase/sale

Number of securities

Price per unit

(b) Cash-settled derivative transactions

Class of relevant security	Product description e.g. CFD	Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position	Number of reference securities	Price per unit
0.25p ordinary	Equity swap	Reducing a long position	300	10.9800 GBP
0.25p ordinary	Equity swap	Reducing a long position	322	10.9700 GBP
0.25p ordinary	Equity swap	Reducing a long position	242	10.9724 GBP
0.25p ordinary	Equity swap	Reducing a long position	248	10.9800 GBP
0.25p ordinary	Equity swap	Reducing a long position	253	10.9800 GBP
0.25p ordinary	Equity swap	Reducing a long position	225	10.9800 GBP
0.25p ordinary	Equity swap	Reducing a long position	10,138	10.9794 GBP

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type e.g. American, European etc.

Expiry date

Option money paid/ received per unit

(ii) Exercise

Class of relevant security

Product description e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

(d) Other dealings (including subscribing for new securities)

Class of relevant security

Nature of dealing e.g. subscription, conversion

Details

Price per unit (if applicable)

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

None

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

None

(c) Attachments

Is a Supplemental Form 8 (Open Positions) attached?

NO

Date of disclosure:	11/11/2026
Contact name:	Molly Childs
Telephone number:	+44 20 7144 3714

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
Rule 8.3 of the Takeover Code (the “Code”)

1. KEY INFORMATION

(a) Full name of discloser:	Man Group PLC
(b) Owner or controller of interests and short positions disclosed, if different from 1(a):  The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.
(c) Name of offeror/offeree in relation to whose relevant securities this form relates:  Use a separate form for each offeror/offeree	RHI Magnesita N.V.
(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:
(e) Date position held/dealing undertaken:  For an opening position disclosure, state the latest practicable date prior to the disclosure	10/11/2026
(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?	YES Offeree: Vesuvius plc

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:	€1 ordinary
	Interests		Short positions
	Number	%	Number	%
(1) Relevant securities owned and/or controlled:	1,203,321	2.54
(2) Cash-settled derivatives:	308,577	0.65
(3) Stock-settled derivatives (including options) and agreements to purchase/sell:
TOTAL:	1,511,898	3.19

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b) Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:
Details, including nature of the rights concerned and relevant percentages:

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevant security	Purchase/sale	Number of securities	Price per unit
€1 ordinary	Purchase	1,476	27.7849 EUR
€1 ordinary	Purchase	1,256	27.7849 EUR

(b) Cash-settled derivative transactions

Class of relevant security

Product description e.g. CFD

Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type e.g. American, European etc.

Expiry date

Option money paid/ received per unit

(ii) Exercise

Class of relevant security

Product description e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

(d) Other dealings (including subscribing for new securities)

Class of relevant security

Nature of dealing e.g. subscription, conversion

Details

Price per unit (if applicable)

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

None

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

None

(c) Attachments

Is a Supplemental Form 8 (Open Positions) attached?

NO

Date of disclosure:	11/11/2026
Contact name:	Molly Childs
Telephone number:	+44 20 7144 3714

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

#FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
Rule 8.3 of the Takeover Code (the “Code”)

1. KEY INFORMATION

(a) Full name of discloser:	Man Group PLC
(b) Owner or controller of interests and short positions disclosed, if different from 1(a):  The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.
(c) Name of offeror/offeree in relation to whose relevant securities this form relates:  Use a separate form for each offeror/offeree	Rotork Plc
(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:
(e) Date position held/dealing undertaken:  For an opening position disclosure, state the latest practicable date prior to the disclosure	10/11/2026
(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?	NO

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:	0.5p ordinary
	Interests		Short positions
	Number	%		Number	%
(1) Relevant securities owned and/or controlled:
(2) Cash-settled derivatives:	16,536,540	2.02		11,216	0.00
(3) Stock-settled derivatives (including options) and agreements to purchase/sell:
TOTAL:	16,536,540	2.02		11,216	0.00

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b) Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:
Details, including nature of the rights concerned and relevant percentages:

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevant security

Purchase/sale

Number of securities

Price per unit

(b) Cash-settled derivative transactions

Class of relevant security	Product description e.g. CFD	Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position	Number of reference securities	Price per unit
0.5p ordinary	Equity Swap	Reducing a long position	596	4.9320 GBP
0.5p ordinary	Equity Swap	Reducing a long position	748	4.9325 GBP
0.5p ordinary	Equity Swap	Increasing a long position	949	4.9340 GBP
0.5p ordinary	Equity Swap	Increasing a long position	2,748	4.9340 GBP
0.5p ordinary	Equity Swap	Increasing a long position	202	4.9340 GBP
0.5p ordinary	Equity Swap	Reducing a long position	85,925	4.9327 GBP

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type e.g. American, European etc.

Expiry date

Option money paid/ received per unit

(ii) Exercise

Class of relevant security

Product description e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

(d) Other dealings (including subscribing for new securities)

Class of relevant security

Nature of dealing e.g. subscription, conversion

Details

Price per unit (if applicable)

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

None

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

None

(c) Attachments

Is a Supplemental Form 8 (Open Positions) attached?

NO

Date of disclosure:	11/11/2026
Contact name:	Molly Childs
Telephone number:	+44 20 7144 3714

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

In relation to Landsbankinn’s covered bond auction yesterday, a covered bond exchange offering took place where holders of the series LBANK CBI 26 could sell the covered bonds in the series against covered bonds bought in the auction at a predefined clean price of 100.

No offers were received in the exchange offering.

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
Rule 8.3 of the Takeover Code (the “Code”)

1. KEY INFORMATION

(a) Full name of discloser:	Man Group PLC
(b) Owner or controller of interests and short positions disclosed, if different from 1(a):  The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.
(c) Name of offeror/offeree in relation to whose relevant securities this form relates:  Use a separate form for each offeror/offeree	Spire Healthcare Group plc
(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:
(e) Date position held/dealing undertaken:  For an opening position disclosure, state the latest practicable date prior to the disclosure	10/11/2026
(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?	NO

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:	1p ordinary
	Interests		Short positions
	Number	%	Number	%
(1) Relevant securities owned and/or controlled:
(2) Cash-settled derivatives:	6,249,986	1.55
(3) Stock-settled derivatives (including options) and agreements to purchase/sell:
TOTAL:	6,249,986	1.55

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b) Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:
Details, including nature of the rights concerned and relevant percentages:

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevant security

Purchase/sale

Number of securities

Price per unit

(b) Cash-settled derivative transactions

Class of relevant security	Product description e.g. CFD	Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position	Number of reference securities	Price per unit
1p ordinary	Equity swap	Reducing a long position	18,526	2.4797 GBP

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type e.g. American, European etc.

Expiry date

Option money paid/ received per unit

(ii) Exercise

Class of relevant security

Product description e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

(d) Other dealings (including subscribing for new securities)

Class of relevant security

Nature of dealing e.g. subscription, conversion

Details

Price per unit (if applicable)

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

None

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

None

(c) Attachments

Is a Supplemental Form 8 (Open Positions) attached?

NO

Date of disclosure:	11/11/2026
Contact name:	Molly Childs
Telephone number:	+44 20 7144 3714

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

*1.33 g/t AuEq (1.29 g/t Au, 0.45 g/t Ag, 0.03 % Cu) over 34 m, 3.08 g/t AuEq (3.04 g/t Au, 0.46 g/t Ag, 0.02 % Cu) over 12 m

MONTREAL, Nov. 11, 2026 (GLOBE NEWSWIRE) — Troilus Mining Corp. (“Troilus” or the “Company”) (TSX: TLG; OTCQX: CHXMF; FSE: CM5) is pleased to announce the fifth batch of results from its Z87 optimization drill program at its gold-copper Troilus Project located in north-central Quebec, Canada. The results reported today include eight drill holes totaling 3,195 metres, and form part of the 2026 exploration program outlined in the Company’s March 31, 2026 press release.

The ongoing Z87 optimization program is focused on targeting Inferred material and unsampled material from historic drilling within and around the current Z87 Reserve pit, with the objective of identifying opportunities to improve the mine plan presented in the Company’s Technical Report on September 9^th, 2026.

The current Mineral Resource and Mineral Reserve estimates have an effective date of December 31, 2025, and therefore exclude all results from the 2026 exploration program. The results reported today further demonstrate mineralization in areas that are currently treated as waste or are classified as Inferred in the existing block model, creating potential opportunities for resource conversion, pit and mining sequence optimization, improvements to the strip ratio and mill feed in the early years of operation.

Z87 Intercept Highlights (see Figure 1):

• Hole 87-26-524 intersected 3.08 g/t gold equivalent (“AuEq”) (3.04 g/t Au, 0.46 g/t Ag, 0.02% Cu) over 12 m within a broader interval of 1.33 g/t AuEq (1.29 g/t Au, 0.45 g/t Ag, 0.03 % Cu) over 34 m starting at 207 m downhole from the Z87 hangingwall (Figure 2).
• Hole 87-26-524 also returned 0.78 g/t gold equivalent (“AuEq”) (0.66 g/t Au, 1.06 g/t Ag, 0.08 % Cu) over 131 m, including 1.41 g/t AuEq (1.22 g/t Au, 1.41 g/t Ag, 0.13 % Cu) over 42.4 m starting at 435 m downhole from an area of Inferred material within the Z87 Reserve pit (Figure 2).
• Hole 87-26-536 intersected 1.09 g/t gold equivalent (“AuEq”) (0.88 g/t Au, 3.36 g/t Ag, 0.13 % Cu) over 59.5 m, including 2.32 g/t AuEq (1.92 g/t Au, 7.06 g/t Ag, 0.22 % Cu) over 11 m starting at 485.5 m from an area of inferred material 50 m below the Z87 Reserve pit.
• Hole 87-23-455-EXT26 intersected 0.79 g/t gold equivalent (“AuEq”) (0.61 g/t Au, 1.54 g/t Ag, 0.12 % Cu) over 71 m, including 1.23 g/t AuEq (1.09 g/t Au, 1.90 g/t Ag, 0.09 % Cu) over 21 m starting at 514 m from an area of Inferred material at the base of the Z87 Reserve pit.

Justin Reid, CEO of Troilus, commented, “The Z87 optimization program continues to deliver strong results, reinforcing our belief that significant opportunities remain within and around the current Reserve pit. While our 2026 drilling is not reflected in the Mineral Resource estimate underlying the updated Technical Report published in September, these results will be incorporated into future modelling updates to assess the potential to convert material from waste to ore, reduce the overall strip ratio and provide greater flexibility in future mine plan revisions. We are confident in our existing mine plan, but remain committed to continual improvement and evaluating opportunities to strengthen it.”

Z87 Optimization Program

Z87 was one of two zones previously mined by open pit during the former Troilus operation. Many of the historical drill holes used to define the former mine Reserve were not continuously sampled, leaving intervals of core – in some cases extending for several hundred metres – without assay data. Many of these unsampled intervals are within the Z87 hangingwall.

For the purposes of resource estimation, these unsampled intervals are assigned values equal to one-half of the laboratory detection limit, resulting in significant gaps within the current block model. The ongoing Z87 optimization program is testing whether mineralization extends through these historically unsampled areas, including those currently treated as waste in the mine plan.

The program is also targeting Inferred material within and around the current Z87 Reserve pit to evaluate potential conversion of resources to the Indicated category and possible incorporation into future Mineral Reserve estimates and mine-plan updates.

The results announced today build on earlier 2026 drilling at Z87, including broad intervals encountered in historically unsampled areas of the hangingwall (see press releases dated September 17, August 20, July 7 and June 25, 2026.)

All grades are uncut, and true thicknesses are approximately 75% to 90% of drilled length.

*The NI 43-101 technical report associated with the Mineral Resources and Reserves of the Troilus Project can be found on SEDAR+ at www.sedarplus.ca under the Company’s issuer profile or on the Company’s website at www.troilusmining.com

Figure 1. Plan map with the reported drill hole locations from Z87

Figure 2. Cross section showing results for drillhole 87-26-524.

Z87 Drilling

Hole 87-26-524 was drilled to target both historically unsampled intervals and Inferred material within the Z87 Reserve pit (see Figures 1 and 2). The hangingwall returned 3.08 g/t AuEq over 12 metres within a broader zone of 1.33 g/t AuEq over 34 metres, while the main zone returned 131 metres grading 0.78 g/t AuEq including 2.06 g/t AuEq over 20 metres, which includes 3.27 g/t AuEq over 5 metres. This hole presents significantly more mineralization in the hangingwall than is in the current resource model (Figure 2). The main zone in this area contains Inferred material, which is not included in the current reserve statement. Only Measured and Indicated Resources are eligible for conversion to Mineral Reserves for the mine plan. This drilling supports the potential upgrade of Inferred material to the Indicated category.

Drillhole 87-26-536 returned 1.09 g/t AuEq over 59.5 metres, including 2.32 g/t AuEq over 11 metres from the main zone of Z87, where the current resource model contains Inferred material. This intercept is approximately 50 metres below the Z87 Reserve pit. There are many instances where the current Reserve pit has Inferred material just below its lower limits. By targeting this material, it could result in a larger overall Reserve pit.

Drillhole 87-23-455-EXT26 returned 0.79 g/t AuEq over 71 metres, including 1.23 g/t AuEq over 21 metres from an area of Inferred material at the base of the Z87 Reserve pit, which may result in an upgrade to the resource classification, reduced strip ratio and potentially an expanded Reserve pit, similar to results presented above.  

To date, Troilus has released 47 drill holes totaling 17,716 metres of the now completed Z87 pit optimization program that amounted to approximately 22,800 metres of drilling and includes the targeting of Inferred and unsampled material within and around the Reserve pit shell.

Table 1. Z87 Drill Results

Hole	From (m)	To (m)	Interval (m)	Au Grade (g/t)	Cu Grade (%)	Ag Grade (g/t)	AuEq Grade (g/t)
87-26-518 (-60° dip)
	59	60	1	1.56	0.00	0.25	1.57
	70	90	20	0.19	0.01	0.36	0.21
	123	127.05	4.05	0.33	0.01	0.34	0.35
	155	202	47	0.33	0.05	0.71	0.40
incl	165	166.2	1.2	1.93	0.04	0.80	1.99
incl	171	172	1	2.98	0.11	2.70	3.16
	208	220	12	0.37	0.07	1.13	0.48
incl	212	213	1	1.66	0.26	3.10	2.05
	226	230	4	0.31	0.02	0.41	0.34
87-26-524 (-60° dip)
	22	25	3	0.32	0.00	0.25	0.33
	95	96	1	1.78	0.20	5.20	2.12
	114	121	7	0.76	0.05	1.05	0.85
incl	120	121	1	4.79	0.14	5.10	5.05
	128	130	2	1.70	0.01	1.23	1.73
	177	180	3	0.31	0.06	1.90	0.42
	207	241	34	1.29	0.03	0.45	1.33
incl	218	230	12	3.04	0.02	0.46	3.08
incl	218	219	1	21.10	0.02	0.25	21.13
incl	229	230	1	10.40	0.01	0.25	10.42
	318	363	45	0.27	0.03	0.72	0.32
incl	328	355	27	0.34	0.04	0.94	0.40
incl	330	331	1	1.46	0.37	9.70	2.08
	435	566	131	0.66	0.08	1.06	0.78
incl	476	518.4	42.4	1.22	0.13	1.41	1.41
incl	497	517	20	1.72	0.24	2.32	2.06
incl	497	502	5	3.03	0.16	1.98	3.27
incl	501	502	1	7.59	0.33	5.50	8.10
incl	556	557	1	3.64	0.23	6.60	4.04
87-26-536 (-60° dip)
	26.75	50	23.25	0.42	0.03	0.90	0.47
incl	28	31	3	1.35	0.09	2.53	1.50
incl	49	50	1	2.75	0.03	0.60	2.80
	67	91	24	0.30	0.02	0.86	0.35
incl	77	79.5	2.5	1.85	0.04	1.18	1.91
	111	115	4	0.23	0.03	1.10	0.29
	156	161	5	0.57	0.01	0.39	0.59
	216	219	3	0.77	0.18	3.15	1.04
	261.2	266	4.8	0.17	0.10	0.70	0.30
	275.1	290	14.9	0.33	0.07	0.80	0.43
incl	286	289	3	0.81	0.11	1.50	0.97
	297	316	19	0.17	0.14	1.41	0.38
	353	364	11	0.17	0.04	0.65	0.23
	378	391.7	13.7	0.13	0.05	0.62	0.21
	429	436	7	0.28	0.09	0.89	0.41
	445	480	35	0.34	0.05	1.13	0.43
	485.5	545	59.5	0.88	0.13	3.36	1.09
incl	494	495	1	3.36	0.45	4.60	4.02
incl	511	522	11	1.92	0.22	7.06	2.32
incl	511	512	1	2.84	0.95	19.30	4.37
incl	519.5	522	2.5	5.42	0.21	15.56	5.91
	557.1	573	15.9	0.26	0.01	1.43	0.29
incl	562	563	1	1.68	0.01	8.70	1.81
87-26-537 (-53° dip)
	127	151	24	0.22	0.06	2.56	0.33
incl	137	139	2	1.26	0.17	9.55	1.61
87-26-538 (-55° dip)
	80	84.45	4.45	0.29	0.02	0.58	0.33
	167	172	5	0.22	0.08	3.08	0.37
	180	253	73	0.23	0.07	2.28	0.35
incl	212	229	17	0.55	0.09	3.52	0.72
incl	213	214	1	5.45	0.31	26.10	6.21
	269	271	2	0.33	0.17	3.85	0.61
87-26-539 (-55° dip)
	162	174	12	0.19	0.03	0.44	0.24
	200	226	26	0.20	0.08	2.74	0.35
incl	221	222	1	3.40	0.04	8.50	3.57
	235	244	9	0.18	0.03	1.16	0.23
	255	268	13	0.47	0.07	2.35	0.60
87-26-540 (-55° dip)
	77	84	7	0.26	0.04	0.87	0.33
incl	83	84	1	1.43	0.06	2.20	1.54
	115	126.2	11.2	0.21	0.14	1.62	0.42
incl	121	122	1	1.21	0.25	3.80	1.60
	203	215	12	0.21	0.04	0.78	0.27
	224	276	52	0.22	0.09	1.72	0.36
incl	264	269	5	1.13	0.27	4.86	1.55
incl	268	269	1	3.57	0.19	11.90	3.98
	283	285	2	0.26	0.19	5.00	0.59
	300	359	59	0.61	0.12	3.37	0.82
incl	305	317	12	1.26	0.38	8.41	1.88
incl	306	308	2	3.98	1.07	26.15	5.76
incl	307	308	1	6.19	1.34	32.00	8.42
incl	351	352	1	6.57	0.06	15.80	6.86
87-23-455-EXT26 (-53° dip, extended beyond 330 m)
	336	353	17	0.22	0.03	0.44	0.26
	360	370	10	0.25	0.03	0.65	0.30
incl	367.3	368.2	0.9	1.81	0.21	4.30	2.14
	394.7	417	22.3	0.30	0.05	0.45	0.36
incl	398.3	401	2.7	0.77	0.14	0.94	0.96
	425	434.6	9.6	0.54	0.10	2.03	0.69
incl	431.8	432.3	0.5	4.68	0.69	13.50	5.78
	459.3	485	25.7	0.49	0.07	1.78	0.62
incl	459.3	463	3.7	1.60	0.29	5.82	2.07
incl	461.1	462	0.9	3.36	0.42	7.20	4.01
	498	502	4	0.44	0.02	2.10	0.50
	514	585	71	0.61	0.12	1.54	0.79
incl	519.5	520	0.5	4.64	0.98	17.90	6.20
incl	532.5	539.5	7	1.15	0.53	4.19	1.92
incl	555	576	21	1.09	0.09	1.90	1.23
incl	565	565.5	0.5	21.70	0.62	37.60	23.03

^{* AuEq = Au grade + 1.3365 * Cu grade + 0.0136 * Ag grade}

Quality Assurance and Control

During the drill program, one-meter assay samples were taken from NQ core and sawed in half. One-half was sent for assaying at ALS Laboratory in Sudbury, Ontario, a certified commercial laboratory, and the other half was retained for results, cross checks, and future reference. A strict QA/QC program was applied to all samples; which included insertion of one certified mineralized standard and one blank sample in each batch of 25 samples. Every sample was processed with standard crushing to 85% passing 75 microns on 500 g splits. Samples were assayed by one-AT (30 g) fire assay with an AA finish and if results were higher than 3.5 g/t Au, assays were redone with a gravimetric finish. For QA/QC samples, a 50 g fire assay was done. In addition to gold, ALS laboratory carried out multi-element analysis for ME-ICP61 analysis of 33 elements four acid ICP-AES.

Qualified Person

The technical and scientific information in this press release has been reviewed and approved by Nicolas Guest, P.Geo., Exploration Manager, who is a Qualified Person as defined by NI 43-101. Mr. Guest is an employee of Troilus and is not independent of the Company under NI 43-101.

AuEq Disclosure

The formulas used to calculate equivalent values for resources are as follows, for 87 Pit AuEq = Au + 1.3365*Cu +0.0136 Ag, for J Pit AuEq = Au + 1.3618Cu +0.0137 Ag, for SW Pit AuEq = Au + 1.3856Cu +0.01141 Ag, for X22 Pit AuEq = Au + 1.3168Cu +0.0136 *Ag. AuEq was calculated using metal prices of $2,415/oz Au; $4.60/lb Cu and $32.00/oz Ag and recoveries of 84.5% for Au, 86.9% for Ag and 88.1% for Cu in the J pit, 85.9% for Au, 87.6% for Ag and 87.9% for Cu in the 87 pit, 82.1% for Au, 87.1% for Ag and 87.1% for Cu in the SW pit and 85.6 % for Au, 87.0% for Ag and 86.3% for Cu in the X22 pit.

About Troilus Mining Corp.

Troilus Mining Corp. is a Canadian development-stage mining company focused on the systematic advancement of the former gold and copper Troilus Mine towards production. Troilus is located in the tier-one mining jurisdiction of Quebec, Canada, where it holds a large land position of 435 km² in the Frôtet-Evans Greenstone Belt. A technical report completed in September 2026 supports a large-scale 26-year, 50,000-tonne-per-day open-pit mining operation, positioning it as a cornerstone project in North America.

For more information:

Caroline Arsenault
VP Corporate Communications
+1 (647) 276-0050
info@troilusmining.com  

Cautionary Note Regarding Forward-Looking Statements and Information

This press release contains “forward-looking statements” within the meaning of applicable Canadian securities legislation. Forward-looking statements include, but are not limited to, statements regarding the impact of the drill results on the Company, the results of the Technical Report, including, without limitation various project economics, financial and operational parameters such as the timing and amount of future production from the Project, expectations with respect to the IRR, NPV, payback and costs of the Project, anticipated mining and processing methods of the Project; proposed infrastructures, anticipated mine life of the Project, expected recoveries and grades, opportunity to expand the scale of the project, the project becoming a cornerstone mining project in North America; the development potential and timetable of the project; the estimation of mineral resources and reserves; realization of mineral resource and reserve estimates; the timing and amount of estimated future exploration; costs of future activities; capital and operating expenditures; success of exploration activities; the anticipated ability of investors to continue benefiting from the Company’s low discovery costs, technical expertise and support from local communities, the timing and amount of estimated future exploration; and the anticipated results of the Company’s 2026 drill program and their possible impact on the potential size of the mineral resource estimate. Generally, forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “continue”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “will”, “might” or “will be taken”, “occur” or “be achieved”. 

Forward-looking statements are made based upon certain assumptions and other important facts that, if untrue, could cause the actual results, performances or achievements of Troilus to be materially different from future results, performances or achievements expressed or implied by such statements. Such statements and information are based on numerous assumptions regarding present and future business strategies and the environment in which Troilus will operate in the future. Certain important factors that could cause actual results, performances or achievements to differ materially from those in the forward-looking statements include, amongst others, currency fluctuations, the global economic climate, dilution, share price volatility and competition. Forward-looking statements are subject to known and unknown risks, uncertainties and other important factors that may cause the actual results, level of activity, performance or achievements of Troilus to be materially different from those expressed or implied by such forward-looking statements, including but not limited to: there being no assurance that the exploration program or programs of the Company will result in expanded Mineral Resources; risks and uncertainties inherent to mineral resource and reserve estimates; the high degree of uncertainties inherent to feasibility studies and other mining and economic studies which are based to a significant extent on various assumptions; variations in gold prices and other metals, exchange rate fluctuations; variations in cost of supplies and labour; receipt of necessary approvals; availability of financing for project development; uncertainties and risks with respect to developing mining projects; general business, economic, competitive, political and social uncertainties; future gold and other metal prices; accidents, labour disputes and shortages; environmental and other risks of the mining industry, including without limitation, risks and uncertainties discussed in the Company’s latest Annual Information Form, its technical reports and other continuous disclosure documents of the Company available under the Company’s profile at www.sedarplus.ca. Although Troilus has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. Troilus does not undertake to update any forward-looking statements, except in accordance with applicable securities laws.

Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/f52adc06-1e03-46db-b206-82372900958c
https://www.globenewswire.com/NewsRoom/AttachmentNg/5d542d60-6b28-44b0-943c-c7c2cb238dd6

NEW HAVEN, Conn., Nov. 11, 2026 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, November 18 at 9:00 a.m. GMT/4:00 a.m. EST.

A live audio webcast of the presentation will be available here and under “Events and Presentations” on the Investors and Media section of the Company’s website.

About Arvinas

Arvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROteolysis TArgeting Chimera (PROTAC) protein degrader platform, Arvinas is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas, with its partner Pfizer, developed the first U.S. Food and Drug Administration (FDA)-approved PROTAC, a type of heterobifunctional protein degrader, which has been outlicensed to Rigel Pharmaceuticals, Inc. for exclusive global development, manufacturing, and commercialization.

Arvinas is currently progressing multiple investigational drugs through clinical development programs, including ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; ARV-102, targeting LRRK2 for neurodegenerative disorders; ARV-027, targeting the polyglutamine-expanded androgen receptor, or polyQ-AR, in skeletal muscle for spinal-bulbar muscular atrophy, also known as Kennedy’s disease; and ARV-6723, targeting HPK1 for advanced solid tumors. Arvinas has also advanced ARV-806, targeting KRAS G12D for solid tumors, in the clinic, and previously announced plans to seek an out-licensing agreement for any additional clinical trials of ARV-806, including dose expansion or combination clinical trials. Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, visit www.arvinas.com and connect on LinkedIn and X.

Contacts
Investors:
Jeff Boyle
+1 (347) 247-5089
Jeff.Boyle@arvinas.com

Media:
Kirsten Owens
+1 (203) 584-0307
Kirsten.Owens@arvinas.com

Local Veterans in Maryland, Massachusetts, Delaware, and Illinois Each Awarded $5,000 to Help Offset the Cost of Housing or Home Improvements

NORWOOD, Mass., Nov. 11, 2026 (GLOBE NEWSWIRE) — In recognition of Veterans Day, Thrive Dispensaries today announced the winners of its third annual Help on the Homefront campaign. First launched in 2024, Help on the Homefront offers eligible veterans the opportunity to receive $5,000 to help ease the financial burden of housing expenses. Thrive Dispensaries are owned and operated by leading multi-state cannabis operator, MariMed Inc. (“MariMed”)(CSE: MRMD) (OTCQB: MRMD).

Help on the Homefront provides veterans the opportunity to receive financial assistance that could be used toward rent or mortgage payments, essential home repairs or other home improvement projects. The community outreach initiative reflects Thrive Dispensaries’ ongoing commitment to raising awareness of the housing challenges and homelessness affecting veterans nationwide.

From July through October 2026, community members were invited to participate in Help on the Homefront by submitting entries on behalf of themselves or eligible veterans in four states where Thrive Dispensaries are located: Maryland, Massachusetts, Delaware and Illinois.

One veteran in each participating state was selected through a random drawing. The 2026 Help on the Homefront winners are:

• Maryland: Glen Burnie resident Rachel Healy is a veteran of the U.S. Navy having served from 2014 to 2018 onboard the USS Higgins (DDG-76).
• Massachusetts: Middleboro resident Joshua Ferguson is a veteran of the Army National Guard, having served from 2004 until his retirement in 2026.
• Delaware: Wilmington resident Anthony Nesbitt is a veteran of the U.S. Army’s Signal Corps, having served from 2004 to 2007.
• Illinois: Salem resident Leonard Newcomb is a veteran of the U.S. Army, having served from 2006 to 2013.

“On Veterans Day, we’re especially proud to recognize the veterans who have given so much to our country and communities,” said Tim Rasmussen, Vice President of Retail Operations at MariMed. “Through Help on the Homefront, Thrive gets to help provide meaningful assistance to veterans facing housing challenges. Over the past three years, we’ve seen firsthand how this support can make a real difference in veterans’ lives, helping ease their financial burdens and provide stability when it’s needed most. We’re honored to continue this program and give back to those who have given so much to our country.”

Each awardee was recognized with a ceremonial check presentation at a Thrive location in their respective market, providing an opportunity to share their personal stories of service and sacrifice, raise awareness of the financial and housing challenges they face, and foster meaningful connections within their local communities.

About MariMed
MariMed Inc. is a leading multi-state cannabis operator, known for developing and managing state-of-the-art cultivation, production, and retail facilities. Our award-winning portfolio of cannabis brands, including Betty’s Eddies™, Bubby’s Baked™, Vibations™, InHouse™, and Nature’s Heritage™, sets us apart as an industry leader. These trusted brands, crafted with quality and innovation, are recognized and loved by consumers across the country. With a commitment to excellence, MariMed continues to drive growth and set new standards in the cannabis industry. For additional information, visit www.marimedinc.com.

Media Contact:
Zach Galasso
DPA Communications
Email: zach@dpacommunications.com
Phone: (978) 604-5423

Company Contact:
Howard Schacter
Chief Communications Officer
Email: hschacter@marimedinc.com
Phone: (781) 277-0007

JUPITER, Fla., Nov. 11, 2026 (GLOBE NEWSWIRE) — AMG, a strategic partner to leading independent investment management firms globally, announced today that Jay C. Horgen, President and Chief Executive Officer, is scheduled to speak at the TD Cowen 2026 Financials & Fintech Conference on Tuesday, November 17, 2026, at 3:10 p.m. ET.

A live audio webcast will be accessible through AMG’s website at https://ir.amg.com/. A replay of the webcast will also be available through AMG’s website shortly after the event.

About AMG

AMG (NYSE: AMG) is a strategic partner to leading independent investment management firms globally. AMG’s strategy is to generate long‐term value by investing in high-quality independent partner-owned firms, through a proven partnership approach, and allocating resources across AMG’s unique opportunity set to the areas of highest growth and return. Through its distinctive approach, AMG magnifies its Affiliates’ existing advantages and actively supports their independence and ownership culture. As of September 30, 2026, AMG’s aggregate assets under management were approximately $974 billion across a diverse range of private markets, liquid alternative, and differentiated long-only investment strategies. For more information, please visit the Company’s website at www.amg.com.

© 2026 Affiliated Managers Group, Inc. All rights reserved.

AMG Media & Investor Relations
Patricia Figueroa
(617) 747-3300
ir@amg.com
pr@amg.com

• A veteran, trained, and certified 17-person sales force, commenced sales operations this week, providing national coverage with customers responsible for approximately 80% of current U.S. ketamine sales
• Initial supply agreements and preorders are targeted for late 2026, with product shipments scheduled to begin in January 2027

• Efficiencies in blow-fill-seal (BFS) manufacturing and the sales structure are expected to result in gross and net sales margins in excess of 50%, margins commonly associated with innovative drugs
• Innovative, drug/device combination vial provides barriers to competition
• NRx has contracted with German suppliers for additional BFS manufacturing lines to expand its sterile injectable portfolio through the new sales channels

WILMINGTON, Del., Nov. 11, 2026 (GLOBE NEWSWIRE) — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP, “NRx” or “the Company”), a commercial biopharmaceutical company developing medicines that target depression, PTSD and suicidality, today announced that it commenced selling its newly approved preservative-free ketamine providing a guaranteed, U.S.-manufactured supply of a drug listed as in shortage since 2018.

All ketamine injection products currently available in the U.S., having been in short supply since 2018, contain the preservative benzethonium chloride (BZT), which FDA has not determined to be generally recognized as safe and effective (GRASE) for OTC antiseptic hand rubs. NRx’s injectable ketamine is preservative-free and comes in a needle-free blow-fill-seal (BFS) vial with a luer-lock tip that attaches directly to a sterile syringe. NRx’s preservative free-ketamine is being sold by veteran sales representatives, most of whom have decades of experience in the sterile injectable market, and who have existing relationships with purchasers controlling approximately 80% of the current US market.

“By enlisting seasoned sales representatives who already sell sterile injectable drugs, we are able to drive considerable efficiency in costs of sales and marketing,” said Jonathan Javitt, MD, MPH, chief executive officer of NRx. “Our representatives already have strong relationships with hospital and group purchasing responsible for the vast majority of ketamine and other sterile injectable drugs sold in the U.S.”

New packaging for an old drug

NRx has focused on converting sterile injectable products from traditional glass bottles, which are increasingly costly to manufacture, to Blow-Fill-Seal (BFS) technology, in which a polypropyline vial is formed, filled and sealed in a single manufacturing step. Until recently, this technology was only suited to eyedrops and other noninjectable products. The vial’s luer-lock tip attaches directly to a sterile syringe used by the health care professional. These attributes allow preservative-free ketamine and other sterile injectable products to benefit from the same manufacturing and cost of goods sold (COGS) efficiencies as other products implementing BFS technology. NRx has prior experience with the high glass vial COGS during Covid and recognized the potential to restore profitability to old sterile generic products using BFS. At the same time, the inherent cost of BFS manufacturing equipment and the complexity of achieving FDA certification of the luer vial provide meaningful competitive advantages for the Company. While the product seems simple, it is a rigorously-controlled FDA drug/device combination product that required extensive medical device validation for approval.

Needle-free and preservative-free

The NRx product offers needle-free handling and provides safety benefits to pharmacy staff, while reducing staff time. When pharmacists, nurses and doctors draw injectable products from traditional glass vials, they must mount a needle on a syringe, pierce a rubber stopper with a needle, and safely dispose of the needle. CDC estimates that hospital-based health care personnel in the United States sustain approximately 385,000 needlestick and other sharps injuries each year, a figure that likely understates the true burden because it excludes non-hospital settings and surveys indicate that 50% or more of injuries go unreported.^1,2 In addition, the NRx luer vial does not generate “sharps” medical waste, which is costly and complex to dispose of. Staff safety and staff time are at a premium in every U.S. hospital, and customers have applauded the value of the NRx BFS solution.

Under current regulations, inactive ingredients in drugs, including preservatives, must be GRASE – or proven not to be unsafe. The FDA has declined to designate BZT as GRASE. Ketamine, first formulated in 1970, is one of the few remaining old drugs that contain BZT. NRx expects the market to increasingly welcome its preservative-free product as the toxicity of BZT becomes better understood.

NRx has filed a citizen petition asking the FDA to remove BZT from ketamine, and an expert toxicology report is available to the public on the FDA docket.^3,4,5 The report, compiled by a board-certified toxicologist under the supervision of a leading regulatory law firm, documents that patients receiving ketamine at dosages routinely used in hospitals and clinics for labeled indications may be exposed to levels of BZT that exceed the FDA’s published maximum daily intravenous injection exposure of 1 milligram.²

Addressing an ongoing shortage

Ketamine has been listed in shortage since 2018, and customers have indicated a willingness to enter into long-term agreements in exchange for guaranteed supply. When hospitals cannot buy FDA-approved ketamine, they are forced to buy non FDA-approved product from compounding pharmacies. Beyond lacking FDA approval, most states limit the legal maximum beyond use date for compounded sterile products to 90 days^6,7, compared with an initial two-year expiration for the NRx product, which NRx anticipates extending.

Beyond ketamine, federal policymakers have recognized the risk posed by a U.S. sterile injectable drug supply that is largely manufactured overseas and vulnerable to shortages. Traditional, labor-intensive glass-bottle manufacturing of these drugs has not been economically viable in the U.S. for decades. facturing of these drugs has not been economically viable in the U.S. for decades. NRx’s prior experience with glass bottling suggests that the COGS may represent 70% or more of the sales price to hospitals, while the BFS process reduces COGS to less than 20%, restoring old products to commercial viability.  NRx’s ketamine presentation demonstrates that manufacturing of old-line sterile injectable drugs can be reshored to the U.S. for the benefit of American patients, workers and investors.

With the preservative-free ketamine FDA approval achieved, NRx has contracted with German manufacturers of BFS technology to double its manufacturing footprint in South Carolina , creating the potential to add more U.S.-manufactured sterile injectable products.

About NRx Pharmaceuticals Inc.

NRx Pharmaceuticals, Inc. (www.nrxpharma.com), is a commercial-stage biopharmaceutical company developing therapeutics based on its NMDA receptor platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. The Company has been awarded an Abbreviated New Drug Approval (ANDA) for Preservative-Free Ketamine and is seeking New Drug Approval for a presentation of intravenous ketamine (NRX-100) with approved claims for treating depression and suicidality.

In October 2026 the Defense Advanced Research Projects Agency awarded an $11.25 million contract to NRx to conduct a phase 3 trial of its oral drug NRX-101, (D-cycloserine/lurasidone) combined with Robotic Neuronavigated Transcranial Magnetic Stimulation as a one-day treatment for patients with depression. NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression.

Notice Regarding Forward-Looking Statements

The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “plan,” “believe,” “intend,” “look forward,” and other similar expressions among others. These statements relate to future events or to the Company’s future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. The Company has reported regulatory milestones as they have been achieved but has not predicted the outcome of any future regulatory determination. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company’s control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company’s current views with respect to future events and is subject to these and other risks, including uncertainties and assumptions relating to the Company’s operations, results of operations, growth strategy, and, among other things, liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. Except as may be required by applicable law, the Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Contact:
Brian Korb
Managing Partner, astr partners
917-653-5122
brian.korb@astrpartners.com

Media Contact:
Victoria Verdeja
RXMD
305-904-1038
victoria@rxmedyn.com

References

1. Panlilio, A. L., Orelien, J. G., Srivastava, P. U., Jagger, J., Cohn, R. D., Cardo, D. M., & the NaSH Surveillance Group and EPINet Data Sharing Network. (2004). Estimate of the annual number of percutaneous injuries among hospital-based healthcare workers in the United States, 1997–1998. Infection Control & Hospital Epidemiology, 25(7), 556–562. https://doi.org/10.1086/502439
2. Centers for Disease Control and Prevention. (2008). Workbook for designing, implementing, and evaluating a sharps injury prevention program. https://www.cdc.gov/infection-control/media/pdfs/sharps-safety-workbook-2008-p.pdfcdc. Accessed November 9, 2026
3. U.S. Food and Drug Administration. (2019). Safety and effectiveness of consumer antiseptic rubs; topical antimicrobial drug products for over-the-counter human use. Federal Register, 84(71), 14847–14864.
4. U.S. Food and Drug Administration. (n.d.). Inactive ingredient search for approved drug products: Benzethonium chloride. Retrieved October 29, 2026, from https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm
5. https://www.regulations.gov/document/FDA-2025-P-3577-0004
6. United States Pharmacopeia. (2022). General chapter <797> Pharmaceutical compounding—Sterile preparations. In USP–NF. Official November 1, 2023.
7. U.S. Food and Drug Administration. (2023). Current good manufacturing practice—Guidance for human drug compounding outsourcing facilities under section 503B of the FD&C Act [Draft guidance]. https://www.fda.gov/media/88905/download accessed November 9, 2026.